GlassScriptPhysician profile
Rajat Garg
NPI 1144254749
$5,446.23
in general payments reported to CMS, 2019-2025
37 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $244 · 2021: $336 · 2022: $699 · 2023: $731 · 2024: $1,228 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $818.35 | 2019-2023 | Diamondback Coronary |
| Recor Medical INC | $586.29 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Abiomed | $527.88 | 2019-2020 | |
| Medtronic, INC. | $493.50 | 2021-2025 | Symplicity G3, Micra, Hawkone |
| Shockwave Medical, INC | $408.84 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $359.08 | 2019-2025 | Avvigo Guidance System, Overstitch Endoscopic Suturing System, Rotapro |
| Pfizer INC. | $277.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.87 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Novartis Pharmaceuticals Corporation | $218.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $144.56 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $140.47 | 2023-2025 | Verquvo |
| Abbott Laboratories | $139.87 | 2020-2025 | Diamondback Coronary, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $114.71 | 2019 | |
| Alnylam Pharmaceuticals INC. | $96.51 | 2025 | Onpattro |
| Amgen INC. | $87.69 | 2019-2025 | Repatha |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $64.20 | 2021-2024 | Kengreal |
| Novo Nordisk INC | $62.80 | 2023-2024 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $58.09 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $54.47 | 2023 | Arcalyst |
| Balt USA, LLC | $46.24 | 2024-2025 | Prestige Coil System |
| Scpharmaceuticals INC. | $45.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.95 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $42.82 | 2025 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $40.30 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $39.84 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $39.62 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.23 | 2023-2024 | Lifevest |
| Cardiva Medical, INC. | $33.95 | 2023 | Cardiva Vascade 6/7f Vcs |
| Celonova Biosciences, INC. | $33.24 | 2019-2020 | |
| Asahi Intecc USA, INC. | $27.22 | 2025 | Asahi Coronary Wires |
| Kiniksa Pharmaceuticals International, Plc | $25.38 | 2024 | Arcalyst |
| Teleflex LLC | $23.09 | 2025 | Chocolate |
| Amarin Pharma, INC. | $15.70 | 2020 | |
| Daiichi Sankyo INC. | $15.35 | 2025 | Injectafer |
| Gilead Sciences, INC. | $13.71 | 2019 | |
| Cvrx, INC. | $12.36 | 2024 | Barostim Neo System |
| Tactile Systems Technology INC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajat Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.